Azitra, Inc. (AZTR)
NYSEAMERICAN: AZTR · IEX Real-Time Price · USD
0.203
+0.002 (1.15%)
At close: Mar 28, 2024, 3:36 PM
0.201
-0.002 (-1.08%)
After-hours: Mar 28, 2024, 5:38 PM EDT
Company Description
Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases.
It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S.
epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease.
The company was incorporated in 2014 and is based in Branford, Connecticut.
Azitra, Inc.
Country | United States |
Founded | 2014 |
IPO Date | Jun 16, 2023 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 10 |
CEO | Francisco D. Salva |
Contact Details
Address: 21 Business Park Drive, Suite 6 Branford, Connecticut 06405 United States | |
Phone | (203) 489-0183 |
Website | azitrainc.com |
Stock Details
Ticker Symbol | AZTR |
Exchange | NYSEAMERICAN |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $5.00 |
CIK Code | 0001701478 |
ISIN Number | US05479L1044 |
Employer ID | 46-4478536 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Francisco D. Salva | President, Chief Executive Officer and Director |
Travis M. Whitfill M.P.H., Ph.D. | Co-Founder, Chief Operating Officer and Director |
Norman Staskey | Chief Financial Officer, Treasurer and Secretary |
Dr. Mark Sampson | Chief Scientific Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 15, 2024 | 8-K | Current Report |
Mar 15, 2024 | 10-K | Annual Report |
Feb 27, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 26, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 26, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Feb 15, 2024 | 424B5 | Filing |
Feb 14, 2024 | 8-K | Current Report |
Feb 13, 2024 | EFFECT | Notice of Effectiveness |
Feb 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Jan 19, 2024 | FWP | Free Writing Prospectus |